Bhagirathbhai Dholaria, MD

home / authors / bhagirathbhai-dholaria-md

Articles

Highlights from ASH 2024: Optimizing Frontline Therapy in Transplant-Eligible MM

Luciano Costa, MD, PhD;Bhagirathbhai Dholaria, MD;Carl Ola Landgren, MD, PhD ;Muhamed Baljevic, MD, FACP

December 17th 2024

Panelists discuss recent clinical trial findings, including the PERSEUS, CASSIOPEIA, IsKia, and GMMG-HD7 studies, and how these evolving treatment strategies are shaping the approach to frontline therapy for patients with transplant-eligible multiple myeloma.

$Elranatamab in Relapsed or Refractory Multiple Myeloma: Phase 2 MagnetisMM-3 Trial Results$

Elranatamab in Relapsed or Refractory Multiple Myeloma: Phase 2 MagnetisMM-3 Trial Results

Muhamed Baljevic, MD, FACP;Bhagirathbhai Dholaria, MD;Adetola Kassim, MD, MS, FACP;Nisha Joseph, MD;Ajay Nooka, MD, MPH

February 5th 2024

Examine the efficacy and safety of the BCMA-targeting bispecific antibody elranatamab as monotherapy and in combinations from the Phase 2 MagnetisMM-3 trial in patients with relapsed or refractory multiple myeloma.

$First Results From the RedirecTT-1 Study With Teclistamab + Talquestamab Simultaneously Targeting BCMA and GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma$

First Results From the RedirecTT-1 Study With Teclistamab + Talquestamab Simultaneously Targeting BCMA and GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma

Muhamed Baljevic, MD, FACP;Bhagirathbhai Dholaria, MD;Adetola Kassim, MD, MS, FACP;Nisha Joseph, MD;Ajay Nooka, MD, MPH

January 29th 2024

Present initial results from the Phase 1 RedirecTT-1 trial exploring the combination of teclistamab and talquetamab in relapsed/refractory multiple myeloma.

$Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma$

Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma

Muhamed Baljevic, MD, FACP;Bhagirathbhai Dholaria, MD;Adetola Kassim, MD, MS, FACP;Nisha Joseph, MD;Ajay Nooka, MD, MPH

January 29th 2024

Compare outcomes between ide-cel chimeric antigen receptor T-cell (CAR-T) therapy and standard treatment regimens such as pomalidomide and daratumumab combinations in patients with heavily pretreated relapsed and refractory multiple myeloma.

$Real-World Effectiveness of Ixazomib Combined With Lenalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma$

Real-World Effectiveness of Ixazomib Combined With Lenalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma

Muhamed Baljevic, MD, FACP;Bhagirathbhai Dholaria, MD;Adetola Kassim, MD, MS, FACP;Nisha Joseph, MD;Ajay Nooka, MD, MPH

January 22nd 2024

Present real-world data on the efficacy and safety of the ixazomib-lenalidomide-dexamethasone combination in patients with relapsed/refractory multiple myeloma outside of clinical trials.

Outcomes After Biochemical or Clinical Progression in Patients With Multiple Myeloma

Muhamed Baljevic, MD, FACP;Bhagirathbhai Dholaria, MD;Adetola Kassim, MD, MS, FACP;Nisha Joseph, MD;Ajay Nooka, MD, MPH

January 22nd 2024

Examine outcomes such as overall survival, progression-free survival, and response rates in multiple myeloma patients who have experienced biochemical or clinical progression after prior lines of therapy.

$Cancer Network Face-Off: Introduction of Relapsed/Refractory Multiple Myeloma$